Evidence map›Paper›PMID 26369655›Full record

Trial reportClinical drug investigation2015

Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study.

Xue Han, Kui Jiang, Bangmao Wang, Lu Zhou, Xin Chen, Shu Li

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical drug investigation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 4 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Clinical Practice Guideline for Gastritis in Korea.Journal of Korean medical science · 2023
    Guideline
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. [Clinical Practice Guideline for Gastritis in Korea].The Korean journal of helicobacter and upper gastrointestinal research · 2024
    Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xue HanDepartment of Gastroenterology, General Hospital of Tianjin Medical University, No. 154 Anshan Road, Tianjin, 300052, China.
Kui JiangDepartment of Gastroenterology, General Hospital of Tianjin Medical University, No. 154 Anshan Road, Tianjin, 300052, China. jiangkuiBM052615@163.com.
Bangmao WangDepartment of Gastroenterology, General Hospital of Tianjin Medical University, No. 154 Anshan Road, Tianjin, 300052, China. gi.tmuh@sohu.com.
Lu ZhouDepartment of Gastroenterology, General Hospital of Tianjin Medical University, No. 154 Anshan Road, Tianjin, 300052, China.
Xin ChenDepartment of Gastroenterology, General Hospital of Tianjin Medical University, No. 154 Anshan Road, Tianjin, 300052, China.
Shu LiDepartment of Gastroenterology, General Hospital of Tianjin Medical University, No. 154 Anshan Road, Tianjin, 300052, China.
Tianjin Medical University · CNTianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveChronic gastritis frequently progresses into precancerous intestinal metaplasia and intraepithelial neoplasia lesions. Rebamipide is a free radical scavenger and we assessed its efficacy on clinical symptoms, gastric mucosal lesions, pathologic grade, and immunohistochemistry in chronic gastritis patients.

methods178 eligible patients were randomized into treatment and control groups. Both groups followed an optimized lifestyle for 26 weeks, but the treatment group was additionally medicated with rebamipide 0.1 g three times per day. Upper gastrointestinal endoscopy was performed in all patients to evaluate the severity of gastritis by the Modified Lanza Scoring (MLS) and histological changes were evaluated by the Updated Sydney System Score (USSS). Gastric mucosa immunohistochemistry in the treatment group was performed using the intestinal metaplasia markers caudal type homeobox transcription factor 2 (CDX2) and trefoil factor 3 (TFF3) detection.

resultsThere were significant outcome differences between the treatment and control groups regarding the clinical symptom scores (2.62 ± 1.86 vs. 1.55 ± 1.61, P = 0.0001), gastric mucosal lesion scores (0.57 ± 1.05 vs. 0.16 ± 0.90, P = 0.002), and inflammation (P < 0.05). Only in the treated patients were the rates of intestinal metaplasia (P = 0.017 vs. P = 0.123) and low-grade intraepithelial neoplasia (P = 0.005 vs. P = 0.226) significantly reduced after 26 weeks. The percentages of CDX2 (31.5 vs. 15.7%, P = 0.021) and TFF3 (44.9 vs. 25.8%, P = 0.012) expressing gastric mucosa cells were significantly lower after rebamipide medication than pre-treatment values.

conclusionsRebamipide improved the clinical symptoms, gastric mucosal lesions, and pathological grades of chronic gastritis patients and decreased the expression rates of CDX2 and TFF3 in gastric cells.

Indexed as

Disease ProgressionAlanineCDX2 Transcription FactorFemaleGastric MucosaGastritisHelicobacter InfectionsHomeodomain ProteinsHumansMaleMetaplasiaMiddle AgedPeptidesPrecancerous ConditionsQuinolonesStomach NeoplasmsAlanineCDX2 protein, humanCDX2 Transcription FactorHomeodomain ProteinsPeptidesQuinolonesrebamipideTFF3 protein, humanTrefoil Factor-3

Identifiers

PMID26369655
OpenAlexW2173852212

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.